<DOC>
	<DOCNO>NCT00986778</DOCNO>
	<brief_summary>Combination therapy entecavir 1.0 mg plus adefovir 10 mg superior antiviral activity compare either entecavir monotherapy 1.0 mg adefovir 10 mg plus lamivudine 100 mg Chinese adult lamivudine-resistant chronic hepatitis B infection</brief_summary>
	<brief_title>Entecavir Plus Adefovir Lamivudine-Resistant Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>CHB HBeAg ( + ) Subject Lamivudine treatment history must LVDr substitution rtM204V/I Naïve nucleoside/nucleotide analogues except LVD HBV DNA &gt; 17,200 IU/mL Compensated liver function Serum ALT &lt; 10 × ULN Women pregnant breastfeed Evidence decompensated cirrhosis Coinfection HIV , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>